Alphabet Replaces Verizon in Dow Jones Industrial Average 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Celltrion just completed the phase 3 trial for its COVID-19 antibody treatment and it has shown very positive results. The biopharmaceutical company headquartered in Incheon, South Korea proves the efficacy of its treatment and full phase 3 results will follow before this month ends.
Outcome of phase 3 tests for the new COVID-19 antibody treatment
Celltrion said on Monday, June 14, that phase 3 of the clinical study for its Rekirona, yielded good results. This means that it was proven to be safe and effective after being tested with volunteer patients from 13 countries worldwide.
As per The Korea Herald, 1,315 patients took part in the third phase trial for Rekirona or CT-P59. The tests were conducted between the months of January and April of this year.
The South Korean biotech company stated that the treatment is effective and significantly reduced the recovery time and rate of progression for acute symptoms of COVID-19. Celltrion discovered through the phase 3 trial that the risk of cases progressing to a severe condition of coronavirus infection was reduced by 70%. In the high-risk group of patients, the progression rate to severe stage was said to have been cut by 72%.
What’s more, those treated with Celltrion’s Rekirona also showed significant results in recovery time as it was shortened. It was said that recovering from the disease was 4.7 to 4.9 days faster compared to others who used other treatments, Yonhap News Agency reported.
Most importantly, it was reported that the Celltrion COVID-19 antibody treatment did not show any serious adverse reaction. Only mild and temporary reactions were noted on the patients during the trial.
Celltrion’s shares surge after Celltrion’s phase 3 trial results were announced
Meanwhile, Pulse News reported that Celltrion’s shares increased by 5.08 percent to ₩279,000 or around $249.69 after the phase 3 test results for Rekirona were revealed. Celltrion Pharm, the company’s drug developing unit’s shares also went up by 12.54 percent to ₩156,200 while Celltrion Healthcare’s shares surged to 5.02 percent to ₩123,500.
In any case, Celltrion will now use the good results to seek marketing approval for the Covid-19 therapy in the U.S. The company will submit the documents to the U.S. Food and Drug Administration and the European Medicines Agency so it can be allowed to sell the treatment in the said regions.
